<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114292</url>
  </required_header>
  <id_info>
    <org_study_id>201812101</org_study_id>
    <nct_id>NCT04114292</nct_id>
  </id_info>
  <brief_title>TUDCA as a Therapy for Ulcerative Colitis (UC)</brief_title>
  <acronym>TUDCA</acronym>
  <official_title>A Phase I Open Label Study of the Efficacy and Safety of Tudca in Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crohn's and Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I open label study examining the efficacy and safety of TUDCA
      (tauroursodeoxycholic acid) in ulcerative colitis treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TUDCA (tauroursodeoxycholic acid) is a dietary supplement that has shown to reduce cellular
      stress related to inflammation. In this Phase I study, patients with active ulcerative
      colitis will be receive TUDCA for six weeks. Safety and tolerability will be assessed.
      Efficacy will be assessed using ulcerative colitis disease activity measurements as well as
      markers of intestinal inflammation before and after treatment. The overall goal of this
      project is to determine TUDCA can provide a new therapeutic option with a desirable safety
      profile for patients with ulcerative colitis focused on the inflamed intestinal epithelium.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Determine the effect of TUDCA treatment on colon inflammation including ER stress in colon biopsy tissues from subjects with symptomatic ulcerative colitis. Secondary: Measure the safety, tolerance and efficacy of TUDCA treatment in symptomatic ulcerative colitis.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label study. All patients will receive TUDCA.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the effect of TUDCA treatment on ER stress in colon biopsy tissues from subjects with symptomatic ulcerative colitis</measure>
    <time_frame>Baseline and post 6 weeks of TUDCA treatment</time_frame>
    <description>Change in ER stress markers as measured by expression of X box binding protein-1 (XBP1), Binding immunoglobulin protein (BIP) and Eukaryotic Translation Initiation Factor 2A (eIF2a) in colon biopsy tissues before and after 6 weeks of TUDCA treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of UC patients for TUDCA safety and tolerability: Adverse events</measure>
    <time_frame>Every 2 weeks after starting TUDCA until 2 weeks after completing 6 weeks of TUDCA treatment. (i.e. study points weeks 2, 4, 6 and 8)</time_frame>
    <description>Monitor and define TUDCA safety/tolerability in this population through frequent monitoring and symptom assessment as detailed in the study procedures. Adverse events will be categorized according to CTCAE v5.0 criteria and grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ulcerative colitis disease activity based on Total Mayo Score</measure>
    <time_frame>Baseline and post 6 weeks of TUDCA treatment</time_frame>
    <description>The Mayo Ulcerative colitis score is an aggregate of individual parameters evaluating rectal bleeding, stool frequency, endoscopic severity and physicians global assessment. Each of these subscores has a range from 0-3 where 3 is worse. a total score can range from 0 to 12 with 0 being in remission and 12 representing the most severe disease. As this is a secondary endpoint in a small trial, patients total scores (out of 12) will be compared from baseline to week 6 using a paired students t test. Mayo score reference is Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation on histology by Goebes index</measure>
    <time_frame>Baseline and post 6 weeks of TUDCA treatment</time_frame>
    <description>The Geboes histology index is a reproducible grading scale for histological assessment of inflammation in ulcerative colitis. This is a six grade classification system for inflammation which can also be fine tuned within each grade. The grades are: 0, structural change only; 1, chronic inflammation; 2, lamina propria neutrophils; 3, neutrophils in epithelium; 4, crypt destruction; and 5, erosions or ulcers. As this is a secondary endpoint in a small trial, patients total scores (out of 20) will be compared from baseline to week 6 using a paired students t test. Higher scores represent more severe disease. The reference for the Geboes index is &quot;Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-9.&quot;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>TUDCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.75-2 grams daily in divided dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tauroursoursodeoxycholic acid, brand name Tudcabil</intervention_name>
    <description>Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day</description>
    <arm_group_label>TUDCA</arm_group_label>
    <other_name>Tudcabil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages Eligible for Study: 18 Years to 65 Years;

          -  Confirmed ulcerative colitis disease through radiographic, endoscopic and/or
             histologic criteria;

          -  Confirmed with active ulcerative colitis (defined as a complete Mayo score ≥ 5 with
             endoscopic subscore of ≥ 1) See Appendix for Mayo Score using recent adaptation to
             include any friability on endoscopy to be scored as &quot;2&quot;.

          -  On a stable dose of medications for inflammatory bowel disease (IBD) (i.e. no change
             in medication within 4 weeks of study enrollment) and not planning to initiate new
             medication other than TUDCA.

        Exclusion Criteria:

          -  Those that received other chemical chaperone therapies in the 3 months prior to
             screening;

          -  Individuals accompanied by gallstones, other intestinal disorders or cancers, or any
             possible cholestatic pathologies that could alter the enterohepatic circulation of the
             bile acids, including previous cholecystectomy or short bowel syndrome;

          -  Subjects with alcohol or drug abuse within the recent year;

          -  Serious heart, lung, kidney, digestive, nervous, mental, or autoimmune diseases

          -  Those with plans for abdominal surgery;

          -  Those unable or unwilling to provide informed consent or failure to comply with the
             test requirements;

          -  Pregnant, lactating women;

          -  Those receiving or planning to receive medicines that inhibit the absorption of the
             bile acids in the intestine;

          -  All female subjects must have birth control and not plan to become pregnant during the
             study. As TUDCA may interfere in the absorption of oral contraceptives, the acceptable
             methods of birth control should include abstinence or 2 of the following intrauterine
             device (IUD-with or without local hormone release), diaphragm, spermicides, cervical
             cap, contraceptive sponge, and /or condoms.

          -  Subjects with baseline liver transamines (AST or ALT) &gt; 1.5 X the upper limit of
             normal.

          -  Patients with complete biliary obstruction and known hypersensitivity or intolerance
             to TUDCA or any of the components of Tudcabil (or to other bile acids).

          -  Patients with moderate-to-severe hepatic impairment.

          -  Evidence of worsening liver function based on the 2 initial laboratory values used to
             establish the baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew A Ciorba, MD</last_name>
    <phone>3142730301</phone>
    <email>mciorba@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lulu Huang</last_name>
    <phone>3142730301</phone>
    <email>luluhuang@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barnes-Jewish West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew A Ciorba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew A Ciorba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew A Ciorba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell. 2008 Sep 5;134(5):743-56. doi: 10.1016/j.cell.2008.07.021.</citation>
    <PMID>18775308</PMID>
  </reference>
  <reference>
    <citation>Adolph TE, Tomczak MF, Niederreiter L, Ko HJ, Böck J, Martinez-Naves E, Glickman JN, Tschurtschenthaler M, Hartwig J, Hosomi S, Flak MB, Cusick JL, Kohno K, Iwawaki T, Billmann-Born S, Raine T, Bharti R, Lucius R, Kweon MN, Marciniak SJ, Choi A, Hagen SJ, Schreiber S, Rosenstiel P, Kaser A, Blumberg RS. Paneth cells as a site of origin for intestinal inflammation. Nature. 2013 Nov 14;503(7475):272-6. doi: 10.1038/nature12599. Epub 2013 Oct 2.</citation>
    <PMID>24089213</PMID>
  </reference>
  <reference>
    <citation>Cao SS, Song B, Kaufman RJ. PKR protects colonic epithelium against colitis through the unfolded protein response and prosurvival signaling. Inflamm Bowel Dis. 2012 Sep;18(9):1735-42. doi: 10.1002/ibd.22878. Epub 2012 Jan 24.</citation>
    <PMID>22275310</PMID>
  </reference>
  <reference>
    <citation>Cao SS, Zimmermann EM, Chuang BM, Song B, Nwokoye A, Wilkinson JE, Eaton KA, Kaufman RJ. The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice. Gastroenterology. 2013 May;144(5):989-1000.e6. doi: 10.1053/j.gastro.2013.01.023. Epub 2013 Jan 18.</citation>
    <PMID>23336977</PMID>
  </reference>
  <reference>
    <citation>Cao SS, Wang M, Harrington JC, Chuang BM, Eckmann L, Kaufman RJ. Phosphorylation of eIF2α is dispensable for differentiation but required at a posttranscriptional level for paneth cell function and intestinal homeostasis in mice. Inflamm Bowel Dis. 2014 Apr;20(4):712-22. doi: 10.1097/MIB.0000000000000010.</citation>
    <PMID>24577114</PMID>
  </reference>
  <reference>
    <citation>Wang S, Kaufman RJ. The impact of the unfolded protein response on human disease. J Cell Biol. 2012 Jun 25;197(7):857-67. doi: 10.1083/jcb.201110131. Review.</citation>
    <PMID>22733998</PMID>
  </reference>
  <reference>
    <citation>Shkoda A, Ruiz PA, Daniel H, Kim SC, Rogler G, Sartor RB, Haller D. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology. 2007 Jan;132(1):190-207. Epub 2006 Oct 21.</citation>
    <PMID>17241871</PMID>
  </reference>
  <reference>
    <citation>Hu S, Ciancio MJ, Lahav M, Fujiya M, Lichtenstein L, Anant S, Musch MW, Chang EB. Translational inhibition of colonic epithelial heat shock proteins by IFN-gamma and TNF-alpha in intestinal inflammation. Gastroenterology. 2007 Dec;133(6):1893-904. Epub 2007 Sep 25.</citation>
    <PMID>18054561</PMID>
  </reference>
  <reference>
    <citation>Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, Thornton DJ, Png CW, Crockford TL, Cornall RJ, Adams R, Kato M, Nelms KA, Hong NA, Florin TH, Goodnow CC, McGuckin MA. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med. 2008 Mar 4;5(3):e54. doi: 10.1371/journal.pmed.0050054.</citation>
    <PMID>18318598</PMID>
  </reference>
  <reference>
    <citation>McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD, Seielstad M. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010 Apr;42(4):332-7. doi: 10.1038/ng.549. Epub 2010 Mar 14. Erratum in: Nat Genet. 2011 Apr;43(4):388.</citation>
    <PMID>20228799</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>tudca</keyword>
  <keyword>tauroursodeoxycholic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04114292/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

